Full-Time
Confirmed live in the last 24 hours
Produces synthetic DNA for biotechnology applications
No salary listed
Senior
Remote in UK
Candidates should be based in the EMEA region and may need to travel to specific countries such as Italy, Netherlands, or the UK for events.
Twist Bioscience specializes in the synthesis of synthetic DNA, which is essential for various applications in biotechnology, pharmaceuticals, and research. The company provides high-quality DNA sequences to a diverse clientele, including academic institutions and pharmaceutical companies, who utilize these products for drug development, disease diagnosis, and genetic research. Twist Bioscience differentiates itself by offering competitive pricing and a proprietary platform that enables quick and accurate DNA production. This platform uses an algorithm to assess the feasibility of synthesizing specific DNA sequences, allowing for instant customer feedback. Their product range includes genes, oligo pools, variant libraries, and tools for SARS-CoV-2, as well as DNA data storage and next-generation sequencing services. The company's goal is to be a leading supplier in the synthetic biology market, providing rapid access to complex DNA sequences that support a variety of research projects.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Twist Bioscience named a Best Idea for 2025 at TD Cowen.
Absci, a pioneer in generative AI-driven drug discovery, and Twist Bioscience, a leader in high-quality synthetic DNA production through its silicon platform, have announced an innovative collaboration to create a novel therapeutic antibody using generative AI.
In other recent news, Twist Bioscience has secured a $15 million capital boost from a new financial agreement with XOMA Royalty Corporation.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator.
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer.